Hot meetings x 3! FDA Microbiome AdComm, Diagnostic devices, ASM-ESCMID developer meeting

Dear All, I think it’s worth a newsletter to call your attention to several upcoming meetings. In addition to the 30 Aug CDC-FDA webinar on “Drug Development Considerations for the Prevention of Healthcare-Associated Infections” and PACCARB’s 12-13 Sep 2022 pandemic wargaming event, we have these 3 meetings. The first two just now hit my radar and the 3rd is worth a shout-out: 

  • 15 Sep 2022 (virtual, 2-4p ET): Duke-Margolis webinar entitled “Advancing Bacterial Diagnostic Development.”
    • Mark McClellan’s team at Duke-Margolis consistently assembles instructive webinars and this one will focus on strategies for regulatory clearance of new diagnostics. Don’t miss it!
    • Go here for more details and to register.
  • 22 Sep 2022 (virtual, 8.30-5.00p ET): FDA Advisory Committee discussing an application for approval of Rebyota (Fecal Microbiota, Live) with a requested indication to “reduce the recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent Clostridioides difficile infection.”
  • 4-7 Oct 2022 (Dublin, Ireland): The 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
    • This series has been one of my favorite meetings since its start … this year it is back and in-person.
    • The scientific program looks excellent and the meeting has lots of opportunity for networking. 
    • I strong encourage attendance! Go here for all the details..

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Share

A Nature Article, a PASTEUR Act Op-Ed, and a VERY Important Phone Number

Dear All, First, Nature published an excellent article entitled “The importance of antimicrobial resistance in medical mycology” by Gow et al. The first sentence of the introduction really packs a punch — “The age of antibiotics, spanning only 80 years, is now entering a period of progressive and widespread emergence of drug-resistant organisms that threaten to bring

Raising awareness of AMR: WHO report on best approaches

Dear All, In addition to forming the inaugural WHO Task Force of AMR Survivors, the WHO has also recently released a report entitled “Awareness-raising on Antimicrobial Resistance: Report of global consultation meetings.”  The report is based on discussions at two meetings held by WHO with stakeholders from across the world. Even before opening the report,

Support the FORWARD and PASTEUR Acts by signing a letter!

Dear All, I’ve written before about the FORWARD Act, a bill introduced last year into Congress with the goal of supporting research in to treatment of endemic fungal diseases with a particular focus on coccidioidomycosis (*). It’s easy to see how this bill and the PASTEUR Act are mutually supportive … both seek to build

WHO Forming Task Force of Antimicrobial Resistance Survivors

Dear All, The WHO has announced a call for expressions of interests from AMR survivors and their caregivers to serve in the inaugural WHO Task Force of AMR Survivors! WHO are specifically looking for both (i) survivors of a drug-resistant infection and (ii) anyone who was a direct caregiver of such a patient. Their goal is

Scroll to Top